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Abstract
Background: CD4+CD25+ T regulatory cells (Tregs) play an important role in regulating immune
responses, and in influencing human immune diseases such as HIV infection. It has been shown that
human CD4+CD25+ Tregs can be induced in vitro by TCR stimulation of CD4+CD25- T cells.
However, the mechanism remains elusive, and intriguingly, similar treatment of murine
CD4+CD25- cells did not induce CD4+CD25+Foxp3+ Tregs unless exogenous TGF-β was added
during stimulation. Thus, we investigated the possible role of TGF-β in the induction of human
Tregs by TCR engagement. We also explored the effects of TGF-β on HIV-1 infection mediated
induction of human Tregs since recent evidence has suggested that HIV-1 infection may also impact
the generation of Tregs in infected patients.
Results: We show here that endogenous TGF-β is key to TCR induction of Foxp3 in human
CD4+CD25- T cells. These events involve, first, the production of TGF-β by TCR and CD28
stimulation and the activation of latent TGF-β by reactive oxygen species generated from the
activated T cells. Biologically active TGF-β then engages in the induction of Foxp3. Neutralization
of active TGF-β with anti-TGF-β antibody or elimination of ROS with MnTBAP abrogated Foxp3
expression. HIV-1 infection enhanced Foxp3 expression in activated CD4+CD25- T cells; which was
also abrogated by blockade of endogenous TGF-β.
Conclusion: Several conclusions can be drawn from this work: (1) TCR and CD28-induced Foxp3
expression is a late event following TCR stimulation; (2) TGF-β serves as a link in Foxp3 induction
in human CD4+CD25- T cells following TCR stimulation, which induces not only latent, but also
active TGF-β; (3) the activation of TGF-β requires reactive oxygen species; (4) HIV infection results
in an increase in Foxp3 expression in TCR-activated CD25- T cells, which is also associated with
TGF-β. Taken together, our findings reinforce a definitive role of TGF-β not only in the generation
of Tregs with respect to normal immune responses, but also is critical in immune diseases such as
HIV-1 infection.
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CD4+CD25+ T regulatory cells (Tregs) have been recog-
nized as the most important immune regulatory cells;
they are involved in immune tolerance, autoimmunity,
inflammation, transplantation, cancer and HIV infection
[1-5]. Human CD4+CD25+ Tregs possess most of the basic
features of their counterparts in mice [6,7], including spe-
cific expression of Foxp3 and immunosuppression of nor-
mal CD4+ responder T cells when co-cultured. Although it
is generally believed that "natural" CD4+CD25+ Tregs are
generated from the thymus, the detailed pathways by
which these Tregs are developed remain elusive [8-11]. In
addition, it has been documented that murine
CD4+CD25+ Foxp3+ Tregs cannot be generated from
peripheral CD4+CD25- naive T cells by TCR plus CD28 co-
stimulation [10-14] unless exogenous TGF-β is included
in the cultures [10,12,15]. In contrast, in humans, some
studies have indicated that stimulation of human periph-
eral CD4+CD25- T cells with anti-TCR and anti-CD28 anti-
bodies can generate CD4+CD25+ T regulatory cells that
also express Foxp3 and are immunosuppressive [16,17].
These findings, although still controversial [15,18], have
raised a critical issue, namely, how to reconcile the
observed induction of Foxp3 and Tregs with the estab-
lished paradigm that the primary goal of T cell activation
by TCR and CD28 is to induce T cell proliferation and dif-
ferentiation to mount specific T cell immunity [19]? Nev-
ertheless, the molecular mechanism underlying TCR-
induction of Foxp3 in human T cells is not understood.
Since TGF-β has been implicated in the induction of Tregs
in murine cells, we set out to investigate whether TGF-β
has a role in the unexpected induction of Tregs by TCR
stimulation in human T cells.
In the human immune system, Tregs play an important
role in regulating immune responses, as well as in control-
ling immune diseases such as infection by viruses that
may impair the immune system. The human immunode-
ficiency virus (HIV) is one such virus, and HIV infection
causes gradual depletion of CD4 T cells in the body.
Recent evidence has indicated that CD4+CD25+ Tregs may
play a role in the pathogenesis of HIV infection [20-23].
The involvement of Tregs in HIV-1 infection appears to be
complicated and may depend on the site of viral replica-
tion and stages of disease progression. In SIV-infected
macaques, Tregs were depleted in the GALT, suggesting a
virus-mediated loss of Treg function that may facilitate
immune activation and productive viral replication [24].
On the other hand, Tregs may also suppress protective
cell-mediated immunity against HIV-1. Depletion of Tregs
in infected patients enhances anti-HIV T cell responses
[25]. Indeed, it has also been shown that the number of
FOXP3+ T cells were significantly increased in lymphoid
tissues of infected patients [26]. The mechanism has been
attributed to HIV-1-mediated promotion of Treg cell sur-
vival [26]. However, the possibility of HIV-1-stimulated
conversion of non-Tregs to Tregs was not addressed.
In this report, we define a novel molecular mechanism
that links TCR stimulation and Foxp3 expression in
human CD4+CD25- T cells. Notably, these events first
involve the production of TGF-β by TCR and CD28
engagement and the activation of TGF-β by ROS produced
from the activated T cells. Biologically active TGF-β then
engages in the induction of Foxp3. The TCR-induced
Foxp3+CD25+ T cells exhibit suppressive activity on TCR-
driven T cell proliferation in CD4+ T cells in vitro. We also
demonstrate that unexpectedly, HIV infection upregulates
Foxp3 expression in TCR-activated CD4+CD25- T cells,
again through TGF-β production. Surprisingly, addition
of exogenous TGF-β inhibits HIV replication in
CD4+CD25- T cells. Our data demonstrate a novel connec-
tion of TGF-β and Tregs in HIV infection of T cells that
may have implications in the Treg activity observed in
vivo in infected patients.
Results
Human CD4+CD25- T cells express Foxp3 upon TCR 
stimulation
We first examined whether TCR stimulation of human
CD4+CD25- T cells induced Foxp3. Human CD4+CD25- T
cells were purified from peripheral blood of normal
healthy donors. As reported [16-18], freshly isolated
human CD4+CD25- T cells possessed undetectable levels
of Foxp3 mRNA and protein (data not shown). TCR stim-
ulation of CD4+CD25- T cells with plate-coated anti-CD3
antibody induced detectable Foxp3 mRNA as determined
by real-time PCR (Fig. 1A) and protein by Western blot
(Fig. 1B) and intracellular Foxp3 staining by flow cytom-
etry (Fig. 1C). Co-stimulation of CD28 further increased
Foxp3 expression (Fig. 1A,B,C), whereas exogenous IL-2
did not have an obvious effect (Fig. 1B). Kinetic studies
showed that both the percentage (Fig. 1C,D) and total
number (Fig. 1E) of CD4+CD25+ Foxp3+ T cells were dra-
matically augmented after 3 days in TCR- and CD28-stim-
ulated CD4+CD25- T cell cultures, although they were
detectable by days 1 and 2 (Fig. 1C,D,E). As expected and
consistent with previous reports [15,27], exogenous TGF-
β significantly upregulated Foxp3 expression in TCR-stim-
ulated human CD4+CD25- T cells (Fig. 1A, and Fig. 2).
Intriguingly, CD25+Foxp3+ T cells were found not only in
non-divided cells, but also in proliferated cells, when
determined by carboxyfluorescein diacetate succinimidyl
ester (CFSE) dilution assay and analyzed by flow cytome-
try (Fig. 2). Of special note. exogenous TGF-β failed to
inhibit T cell proliferation under the current optimal
(anti-CD3+anti-CD28) culture conditions (Fig. 2).
Despite their proliferation, CD25+Foxp3+ T cells induced
by TCR and CD28 stimulation produced only a trivial
amount of intracellular IFN-γ and undetectable IL-4 (dataPage 2 of 16
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CD4+CD25-CD45RO- T cells [18] were stimulated with
anti-CD3 and anti-CD28 antibodies (unpublished
results). Significantly, when the TCR-induced
CD4+CD25+ T cells that contained significant number of
Foxp3+ T cells (Fig. 1) were co-cultured with autologous
CD4+CD25- T responder cells in the presence of autolo-
gous monocytes as APCs, anti-CD3 driven T cell prolifer-
ation was dramatically suppressed (Fig. 3A) and IFN-γ
production was inhibited (Fig. 3B), suggesting their bio-
logically regulatory feature. Thus, TCR and CD28 co-stim-
ulation of CD4+CD25- T cells induces Foxp3 expression,
but the effect is vivid at later stages of cell culture (>2–3
days).
T cell-derived TGF-β is involved in TCR induction of Foxp3 
in human CD4+CD25- T cells
We then sought to determine the underlying molecular
mechanism of the Foxp3 expression in TCR-activated
human CD4+CD25- T cells. We focused on endogenous
TGF-β produced by T cells, since previous studies from our
own and other independent groups [10,12,15,27,28]
have clearly demonstrated that exogenous TGF-β induces
Foxp3 expression in mouse and human CD4+CD25- T
cells (Fig. 1 and Fig. 2). In order to eliminate any possible
contamination by exogenous TGF-β contained in the FBS
that is usually a component of normal complete culture
medium, we used serum-free medium (X-Vivo 20) in our
experiments. We first examined whether TCR and CD28
stimulation of human CD4+CD25- T cells produced TGF-
β. Highly purified human CD4+CD25- T cells were cul-
tured with anti-CD3, and the anti-CD28 antibodies and
TGF-β in the culture supernatants were measured by
ELISA. Since TGF-β is usually secreted as its latent form
(LAP-TGF-β), we first studied the total TGF-β protein (the
supernatants were acid activated with HCl in vitro). TCR-
and CD28-stimulated CD4+CD25- T cells secreted TGF-β1
(Fig. 4A). Kinetic studies revealed that TGF-β production
was time-dependent (Fig. 4A), with barely detectable lev-
els before 48 hrs, but increased significantly after 72 hrs
(Fig. 4A), which was positively correlated with the Foxp3
expression (Fig. 1C,D). Since only biologically active TGF-
β (removal of latency-associated peptide [LAP]) can bind
to its receptors and execute signal transduction [29], we
then measured the levels of active TGF-β (without HCl
treatment in vitro) in the cultures. To our surprise, active
TGF-β1 was also augmented following the stimulation
(Fig. 4A). Importantly, the proportion of active TGF-β to
the total TGF-β increased in a time-dependent manner,
with about 37% at 24 hrs to almost 65% at 72 hrs (Fig.
4B), whereas the ratio was not changed (even decreased)
in medium-treated cultures (Fig. 4B). Finally, TGF-β pro-
tein in the CD4+CD25- cell lysates was analyzed by west-
ern blot. Stimulation of TCR and CD28 induced TGF-β
production, which appeared at 48 hrs and further
increased thereafter (data not shown). Thus, TGF-β was
not only produced and secreted, but also activated by TCR
and CD28 stimulation in human CD25- T cells.
To provide evidence that TGF-β signal transduction was
activated in TCR- and CD28-stimulated T cells, phospho-
rylation of Smad2 (P-Smad2), a critical down-stream step
in the TGF-β signaling pathway, was examined in TCR-
stimulated CD4+CD25- T cells. Western blot analysis
revealed that P-Smad2 was positive in TCR-stimulated
CD25- T cells (Fig. 4C). As a positive control, inclusion of
exogenous TGF-β in the cultures dramatically upregulated
the levels of P-Smad2 (Fig. 4C), which was positively cor-
related with the increase in Foxp3+ T cells (Fig. 2). Most
importantly, to confirm that the TGF-β produced and acti-
vated in TCR-activated CD25- T cells was indeed responsi-
ble for Foxp3 expression, an anti-TGF-β monoclonal
antibody (clone 1D11) was included in the culture that
could abolish all three isoforms of active TGF-β1,2, and 3.
Addition of anti-TGF-β antibody dramatically reduced
TCR-induced Foxp3 mRNA (data not shown) and protein
by either Western blot analysis (Fig. 5A) or by intracellular
Foxp3 staining (Fig. 5B,C). Quantitative analysis of the
WB bands revealed that neutralization of TGF-β with anti-
TGF-β antibodies almost completely abrogated the Foxp3
induction in TCR-stimulated CD4+CD25- T cells (more
than 200-fold decrease), whereas exogenous TGF-β fur-
ther enhanced TCR-induced Foxp3 expression (6- and
3.5-fold increase compared to αCD3 and aCD3+αCD28
treated cells respectively). The effect of TGF-β neutraliza-
tion on Foxp3 reduction was seen most significantly after
72 hrs of culture (Fig. 5C). Despite the great degree of var-
iability among individuals, anti-TGF-β antibody consist-
ently downregulated CD25+Foxp3+ T cells (Fig. 5C).
Taken together, these data clearly demonstrate that T cell-
derived TGF-β is required for TCR induction of Foxp3 in
human CD25- T cells in culture.
TCR and CD28 stimulation produces ROS in human 
CD4+CD25- T cells
Since TCR and CD28 stimulation of human CD4+CD25- T
cells produced biologically active TGF-β (Fig. 4) that was
responsible for Foxp3 induction (Fig. 5), we then studied
what caused production of active TGF-β. We focused on
ROS that could be produced by TCR stimulation in CD4+
T cells [30-32] and are involved in the activation of latent
TGF-β [33-35]. Intracellular ROS can be quantified by
staining with dihydroethidium (DHE) that is selectively
oxidized by superoxide anion (O2-) to the fluorescent
product ethidium bromide, which can be measured by
flow cytometry. Freshly purified CD4+CD25- T cells were
positive for ROS by DHE staining with low mean fluores-
cence intensity (MFI = 30–50, Fig. 6B). During the course
of cell culture, from days 1 through 5, the MFI of ROS of
the live cells in the cultures with medium alone was stablePage 3 of 16
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TCR stimulation of human CD4+CD25- T cells induces Foxp3Figure 1
TCR stimulation of human CD4+CD25- T cells induces Foxp3. Highly purified CD4+CD25- T cells (98–99%) were stimulated 
with the indicated regimen in X-Vivo 20 serum-free medium, and Foxp3 mRNA and protein were examined. A. Cells were cul-
tured for 48–72 hours. RNA was isolated and cDNA synthesized for assessing the expression of Foxp3 by real-time PCR. 
Freshly isolated CD4+CD25+ T cells were used as a positive control for Foxp3 expression. Values are expressed as the nor-
malized ratio of Foxp3 to GAPDH. B. Analysis of Foxp3 protein with Western blot. The experiments were repeated three 
times with similar results. C-E. Analysis of intracellular Foxp3 protein at the single-cell level by FACS. Freshly isolated 
CD4+CD25- cells (Fresh) or cultured cells at the indicated time were stained with FITC-anti-CD25 (surface) and PE-anti-Foxp3 
(intracellular) and analyzed on FACScalibur. A representative FACS profile is shown as dot plots of CD25 versus Foxp3 (C). The 
quadrant gates were set according to the negative isotype control antibodies in the respective cells. The kinetics of the per-
centage (D) and total number (E) of CD25+Foxp3+cells are shown as Mean ± SD of each group at each time point (n = 3 to 6). 
Med: Medium; αCD3: anti-CD3 mAb; αCD28: anti-CD28 mAb. * indicates a different donor.
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Foxp3+ T cells exist in both non-proliferating (CFSE+hi) and dividing (CFSE+low) TCR-stimulated CD4+CD25- T cellsigure 2
Foxp3+ T cells exist in both non-proliferating (CFSE+hi) and dividing (CFSE+low) TCR-stimulated CD4+CD25- T cells. 
CD4+CD25- T cells were labeled with CFSE (2.5 μM) and cultured with anti-CD3 and anti-CD28 for 3 and 5 days. Cells were 
then counter-stained intracellularly with PE-conjugated anti-Foxp3 antibody. The cells were analyzed with FACS and a repre-
sentative profile of CFSE vs. Foxp3 or its control antibody (mIgG2a) is displayed. The experiments were repeated three times 
with similar results. Data not shown here are the cultures with cells in medium alone. No CFSE dilution (CFSE+low) or Foxp3+ 
cells were observed.
Retrovirology 2007, 4:57 http://www.retrovirology.com/content/4/1/57
Page 6 of 16
(page number not for citation purposes)
TCR induced CD25+Foxp3+ T cells were immunosuppressive to CD4+CD25- T cell proliferation in vitroFigure 3
TCR induced CD25+Foxp3+ T cells were immunosuppressive to CD4+CD25- T cell proliferation in vitro. A. CD4+CD25- T 
cells were cultured with anti-CD3 and anti-CD28 for 5 days. The converted CD4+CD25+Foxp3+ T cells were purified and 
washed extensively. The converted Tregs were then used at varying concentrations in a co-culture suppression assay along 
with CD4+CD25- (5 × 104) T cells pre-labeled with CFSE as responders and autologous monocytes (2 × 105) as accessory cells. 
Anti-CD3 antibody was added into the start of the co-culture suppression assay (0.5 μg/ml). CFSE dilution of responder cells 
was measured after 72 hrs using flow cytometry. B. IFN-γ production of responder cells in the co-culture assay as detected by 
flow cytometry after 72 hrs. iTreg: induced Foxp3+CD4+CD25+ T cells. The experiment was repeated for three times with 
similar results.
Retrovirology 2007, 4:57 http://www.retrovirology.com/content/4/1/57at the baseline level (Fig. 6A, B). Anti-CD3 and anti-CD28
stimulation did not induce any increase in ROS produc-
tion in the CD25- T cells by day 1 and only slightly
enhanced it by day 2 (Fig. 6A,B and Fig. 7). However, by
day 3 of cultures, the levels of ROS in TCR- and CD28-
stimulated CD25- T cells were dramatically upregulated
and continued to increase at day 5 (Fig. 6A,B and Fig. 7B).
Interestingly, the increase in ROS in TCR- and CD28-stim-
Neutralization of endogenous TGF-β abrogated TCR-ind ced Foxp3 expressioFig e 5
Neutralization of endogenous TGF-β abrogated TCR-
induced Foxp3 expression. A. Western blot analysis of 
Foxp3 protein in cultured CD4+CD25- T cells with indicated 
reagents (72 hrs). B. FACS analysis of intracellular Foxp3 
protein cultured with TCR and CD28 in the presence of anti-
TGF-β1,2,3 (αTGF-β) or control (mIgG1) antibodies (72 hr). 
The data are shown for a representative donor. The values 
are presented as the percentage of CD25+Foxp3+ T cells. C. 
CD25+Foxp3+ T cells (%) in the TCR- and CD28-stimulated 
CD4+CD25- T cells in the absence (-) or presence of anti-
TGF-β1,2,3 antibody (αTGF-β) at days 3 and 5. Each symbol 
represents one donor.
TCR and CD28 stimulation of human CD4+CD25- T cells produced TGF-β and exhibited phosphorylation of Smad2Figure 4
TCR and CD28 stimulation of human CD4+CD25- T cells 
produced TGF-β and exhibited phosphorylation of Smad2. 
A. CD4+CD25- T cells (1 × 106/ml) were cultured with anti-
CD3 and anti-CD28 in X-Vivo 20 serum-free medium for the 
indicated time points. Cell-free supernatants were either 
untreated (for active TGF-β) or treated with 1 N HCl (for 
total TGF-β) followed by ELISA for TGF-β1 measurement. 
The values are shown as Mean ± SD of individuals in each 
group at each time point (n = 3 to 9). B. The relative ratio of 
active to total TGF-β is shown in each time point as in A. C. 
Western blot analysis of P-Smad2 in cultured CD4+CD25- T 
cells (72 hrs). Whole cell lysis protein (70 μg/ml) was loaded 
into each lane. P-Smad2 was detected with anti-P-Smad2 
antibody. α-tubulin was used as host protein control. 3+28: 
anti-CD3+anti-CD28; Med: medium.Page 7 of 16
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TCR and CD28 stimulation induced ROS production and increased T cell apoptosisFigure 6
TCR and CD28 stimulation induced ROS production and increased T cell apoptosis. CD4+CD25- T cells were stimulated with 
anti-CD3 and anti-CD28 antibodies for the indicated time points and then intracellular ROS was stained with DHE. The mean 
fluorescence intensity (MFI) of DHE in a single cell was measured with FACS. A aliquot of cells was stained with Annexin-V and 
7-AAD to analyze the early apoptotic (Annexin-V+7-AAD-) and late apoptotic/dead (Annexin+7-AAD+) cells. The cells from 
each cultured well were also examined for viable cells by trypan blue exclusion assay. A. A representative histogram profile of 
DHE staining on the different days. The filled histogram is the un-labeled cells (negative control). B. The values are displayed as 
the Mean ± SD of the MFI of DHE between stimulated (αCD3+αCD28) and non-stimulated (medium) live T cells (R1 gated 
cells in Fig. S1) at the indicated time points (n = 2 to 5). C. The values are presented as the Mean ± SD of the early apoptotic 
(Annexin+7-AAD-) and dead/late apoptotic (Annexin+7-AAD+) between anti-CD3 and anti-CD28 (3+28) and non-stimulated 
(medium) cells (n = 2 to 5). D. The values are shown as the Mean ± SD of the live cells (trypan blue negative) per well. The 
original cell number was 1 × 106 per well(24-well plate; n = 2 to 5).
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A representative FACS profile of cell size (A), DHE fluorescence (B) and apoptotic cells (C) between anti-CD3 plus anti-CD28-stimulated and medium-treated CD4+C 25- T cells is displayedFigure 7
A representative FACS profile of cell size (A), DHE fluorescence (B) and apoptotic cells (C) between anti-CD3 plus anti-
CD28-stimulated and medium-treated CD4+CD25- T cells is displayed. A. Profile of FSC vs SSC is displayed to show the cell 
size. The cells were electronically gated as two populations based on their size. R1 (red) represents live or early apoptotic cells 
(see C). R2 (green) represents dead and/or late apoptotic cells (see C). B. Profile of DHE fluorescence (ROS+) on FL-2 vs. FSC 
of R1 and R2 cells. The values are shown as the MFI of R1 and R2 cells (R1/R2). Data not shown here are the MFI of unlabeled 
cells (negative control for DHE staining) on FL2, which is usually < 10. C. The profile of Annexin-V vs. 7-AAD staining of cul-
tured cells compensating the R1 and R2 regions as gated in A. The quadrant gates were set according to the negative isotype 
control antibodies in the respective cells.
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enhancement of active TGF-β production (Fig. 4A) and
Foxp3 expression (Fig. 1). Significantly, anti-CD3 and
anti-CD28 stimulation gradually up regulated apoptotic
cells (Annexin-V+7-AAD-) when compared with the
medium-alone control cultures (Fig. 6C and Fig. 7C),
despite the similar percentages of late apoptotic/dead cells
between the two conditions (Fig. 7C). Consequently, the
total apoptotic/dead cells (Annexin-V+7-AAD- and
Annexin-V+7-AAD+) were elevated dramatically in TCR-
and CD28-stimulated cultures after 3 days (Fig. 6C, 7C),
which corresponded with the increase in ROS production
(Fig. 6C, 3B). Of special note, the dead/late apoptotic T
cells were smaller (Fig. 7A, R2 green) and stained positive
for Annexin-V and 7-AAD (Fig. 7C). They exhibited higher
MFI of ROS (Fig. 7B) than that of live (Annexin-V-7-AAD-
) or early apoptotic (Annexin+7-AAD-) cells in the same
cultures (Fig. 7B). Despite the increase in apoptotic/dead
cells, TCR and CD28 co-stimulation enhanced the overall
total number of live cells (Trypan blue negative) in the
culture, whereas the total number in the medium-alone
wells was decreased (Fig. 6D).
To determine the presence and amount of extracellular
ROS, the supernatants from the activated T cells were
incubated with a non-fluorescent 2'7'-dichlorofluorescin-
diacetate (DCFH-DA) that could be oxidized into fluores-
cent 2', 7'-dichlorofluorescein (DCF) by ROS in aqueous
solution at 37°C. As expected, the supernatants from the
cultures with medium alone had undetectable ROS (Fig.
8) and remained unchanged during days 2,3, and 5 as
reflected by a consistent background of DCF fluores-
cence(Fig. 8). However, the supernatants in the cultures of
CD25- T cells stimulated with anti-CD3 and anti-CD28
antibodies contained large amounts of ROS (Fig. 8). The
extracellular ROS was significantly enhanced by 48 hours
and reached the peak at 72 hours (Fig. 8). Thus, TCR acti-
vated CD4+CD25- T cells produce ROS and also release
them into the cultures.
ROS produced in activated CD4+CD25- T cells are 
associated with Foxp3 induction through activation of 
TGF-β
To determine the role of ROS in the upregulation of Foxp3
expression through activation of TGF-β, a superoxide dis-
mutase mimetic, Mn(III)tetrakis (5,10,15,20-benzoic
acid) porphyrin (MnTBAP), that inhibits intracellular and
neutralizes extracellular ROS [32,34,36] was included in
the CD3 and CD28 co-stimulated CD4+CD25- cell cul-
tures. The addition of MnTBAP significantly reduced ROS
production in TCR stimulated CD25- T cells; the reduction
was most obvious at days 3 and 5 (Fig. 9A,B). Impor-
tantly, the active TGF-β was almost completely abrogated
in the same cultures with MnTBAP (Fig. 9B), although the
total TGF-β was also decreased (data not shown). Unex-
pectedly, when intracellular Foxp3 was examined, it was
found that the TCR-induced CD25+Foxp3+ T cells were
dramatically reduced in MnTBAP treated cells (Fig. 9C).
Thus, ROS produced by TCR activated CD25- T cells plays
a role in active TGF-β production, and the TGF-β produc-
tion in turn induces Foxp3 expression in human
CD4+CD25- T cells.
HIV infection upregulates Foxp3 expression in TCR-
activated CD4+CD25- T cells via TGF-β
Although CD4+CD25+ Tregs have been indicated in the
pathogenesis of HIV infection, it is unknown how these
Tregs are generated and regulated. We further studied
whether HIV infection and replication affected Foxp3
expression in human CD4+CD25- T cells. Purified
CD4+CD25- T cells were infected with HIV for 2 hours, fol-
lowed by extensive washes to remove any unbound virus
[37]. The HIV-infected CD25- T cells were then cultured
with anti-CD3 and anti-CD28 antibodies in serum-free X-
Vivo medium. Intracellular Foxp3 was examined at days 3
and 5 by flow cytometry. Surprisingly, HIV infection dra-
matically increased Foxp3 expression in TCR-stimulated
CD25- T cells compared to those without virus infection
(58% vs. 18%) (Fig. 10A). Consistent with the data of
uninfected CD25- T cells (Fig. 5), neutralization of TGF-β
The cell-free supernatant from TCR stimulated CD4+CD25-  cell culture contained ROSFigur  8
The cell-free supernatant from TCR stimulated CD4+CD25- 
T cell culture contained ROS. CD4+CD25- T cells were cul-
tured with anti-CD3 and anti-CD28 for the indicated time 
points and ROS in the culture supernatant was detected 
using DCFH-DA as described in the Method section. Oxida-
tion of DCFH-DA was measured using a spectrofluorometer 
at wavelength 485/535 nm and is represented as fluorescent 
units. The experiment was repeated twice with similar 
results.Page 10 of 16
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Neutralization of ROS with MnTBAP abrogated active TGF-β and reduced CD25+Foxp3+ T cellsFig e 9
Neutralization of ROS with MnTBAP abrogated active TGF-β and reduced CD25+Foxp3+ T cells. CD4+CD25- T cells were cul-
tured with anti-CD3 and anti-CD28 antibodies in the presence or absence of MnTBAP (100 μM) for 3 and 5 days. The intrac-
ellular ROS production was determined by DHE staining. Active TGF-β in the supernatants was determined with ELISA. The 
intracellular Foxp3 protein was determined by FACS staining. A. A representative overlay of histograms of ROS in the cultured 
T cells with (+MnTBAP) and without (-MnTBAP) MnTBAP at days 3 and 5. The filled histograms were from unlabeled cells as 
negative control for DHE staining. The experiment was repeated three times with similar results. B. The values are shown as 
the Mean ± SD of active TGF-β1 in the culture supernatants at days 3 and 5 (n = 2). C. MnTBAP reduced CD25+Foxp3+ T 
cells. Each symbol represents one individual.
Retrovirology 2007, 4:57 http://www.retrovirology.com/content/4/1/57with anti-TGF-β1,2,3 antibody reduced Foxp3 expression
in HIV-infected CD25- T cells (Fig. 10A), although the
antibody had little effects on HIV replication (Fig. 10B).
On the other hand, addition of exogenous active TGF-β
further enhanced Foxp3 expression in HIV infected cells,
which reached about 70–80% of CD25+Foxp3+ cells at
day 5 (Fig. 10A). Thus, HIV infection enhances Foxp3
expression through TGF-β in TCR-activated human CD25-
T cells.
Discussion
Of the many unresolved questions regarding Tregs, the
issue of the factors and/or molecules regulating Foxp3
expression remains significant. In this report, using a
serum-free culture system, we have provided the first evi-
dence that endogenous TGF-β produced by TCR and
CD28 engagement and activated by ROS plays a critical
role in Foxp3 induction in human CD4+CD25- T cells.
Several important conclusions can be drawn from the cur-
rent work.
Firstly, TCR and CD28 stimulation indeed upregulates
Foxp3 expression at both the mRNA and protein levels,
but the significance is only seen later (>2–3 days) in the
cultures, suggesting that Foxp3 expression (generation of
Tregs) is not an early event during T cell responses. Inter-
estingly, Foxp3+CD25+ T cells can be observed not only in
non-dividing (CFSEhi), but also in proliferating popula-
tions (CFSElow). However, it remains unknown whether
Foxp3 is induced first, followed by T cell proliferation, or
induced during or after proliferation. The de novo induc-
tion of Foxp3 is supported by the observation that
CD4+CD25-CD45RO- T cells express Foxp3 upon TCR and
CD28 stimulation (Fig. 4), although they lack Foxp3
mRNA and protein before culture [18].
Secondly, TGF-β serves as a link in TCR-induction of
Foxp3 in human CD4+CD25- T cells. TCR and CD28 stim-
ulation of CD25- T cells produces not only latent, but also
active TGF-β in the cultures. Intriguingly, active TGF-β is
not produced significantly until later in cell culture; this
timing correlates with the kinetics of Foxp3 expression in
T cells. The levels of remaining active TGF-β in the culture
supernatants reach 200–300 pg/ml (per 1 × 106 cells) after
day 3, which is a dose approximately sufficient to induce
significant Foxp3 in murine CD4+CD25- T cells [12] (data
not shown). It should be noted that TCR and CD28 stim-
ulation alone fails to induce detectable levels of active
TGF-β and induces minimal total TGF-β in the culture
supernatants when murine CD4+ or CD4+CD25- T cells (1
× 106/ml) are used [38,39] (our unpublished data). The
lack of sufficient TGF-β production may explain the inef-
fectiveness of Foxp3 induction in murine CD4+CD25- T
cells upon TCR and CD28 stimulation [10,12,15,27]. The
fact that exogenous active TGF-β further upregulates
Foxp3 expression in TCR-stimulated CD25- human T cells
provides additional evidence of its indispensable role. Of
note, under the optimal stimulation (anti-CD3 and anti-
CD28), exogenous TGF-β1 (2 ng/ml) fails to inhibit T cell
proliferation (Fig. 2), but still dramatically augments
Foxp3+ T cells. The failure of TGF-β inhibition of T cell
HIV infection upregulated Foxp3 expression in TCR activated CD4+CD25- T cellsFigure 10
HIV infection upregulated Foxp3 expression in TCR activated 
CD4+CD25- T cells. A. Purified CD4+CD25- T cells were 
infected with HIV1 (HIV NLA-3) and cultured with anti-CD3 
and anti-CD28 antibodies in the absence (HIV-1) or presence 
of active TGF-β1 (2 ng/ml) (HIV-1+TGF-β) or anti-TGF-
β1,2,3 antibody (HIV-1+anti-TGF-β) for 3 (data not shown) 
and 5 days. T cells were then stained for surface CD25 and 
intracellular Foxp3. A representative of two experiments is 
displayed. A parallel culture of TCR- and CD28-stimulated 
CD25- T cells without HIV infection (uninfected) was used as 
control. B. The supernatants from the same cultures in A 
were collected at the indicated time points and tested for 
HIV p24 with ELISA. The experiment was repeated twice 
with similar results.Page 12 of 16
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induced by optimal signals (CD3+CD28) [40,41]. The
data, however, argue against the notion that TGF-β may
selectively inhibit CD25-Foxp3- T cells, consequently
enhancing the frequency of the minor population of
CD25-Foxp3+ T cells. In support of a critical role of TGF-β
signaling in the induction of Foxp3, we have observed
that CD4+CD25- T cells from conditional knockout mice
with T-cell specific deletion of TGF-β receptor I fail to
become Foxp3+ Tregs upon TCR and exogenous TGF-β
stimulation in cultures (unpublished data). Moreover,
Smad2, a critical mediator of the TGF-β signal pathway, is
phosphorylated in anti-CD3 and CD28 cultured cells,
indicating that the TGF-β signal is transduced. Most
importantly, depletion of active TGF-β in the cell cultures
with anti-TGF-β1,2,3 antibody abrogated TCR and CD28
induced Foxp3 expression; such abrogation is also evident
in TCR-activated CD4+CD25-CD45RO- T cells (data not
shown). Thus, TGF-β is a key molecule in TCR-induction
of Foxp3 in human CD4+CD25- T cells.
Now that endogenous TGF-β has been established to be
responsible for TCR induction of Foxp3 in human
CD4+CD25- T cells, one immediate question is how bio-
logically active TGF-β is produced. TGF-β is usually
secreted as a latent form in which the active portion is
masked with a latency-associated peptide (LAP) [42].
Newly produced latent TGF-β has to be activated by
removing the LAP in order to bind to its receptors and exe-
cute signal transduction [43]. Since both latent and active
TGF-β are present in the supernatants of TCR- and CD28-
stimulated cultures, and indeed active TGF-β is the func-
tional molecule, the question remains as to how latent
TGF-β is activated.
The finding that TGF-β is produced/secreted at the late
stage of T cell activation, following maximal secretion of
most Th1 and Th2 cytokines, may resolve the current par-
adox of TCR and CD28 induction of Foxp3 (a regulatory
T cell gene) and consequent immune tolerance. It is pos-
sible that timing is a critical factor. The primary goal of a
T cell response by TCR and CD28 stimulation is to pro-
duce IL-2 that enables T cells to proliferate and differenti-
ate into Th1 and/or Th2 cells to mount specific immunity
[19]. Afterwards, a suppressive factor, TGF-β, is produced/
activated, which would provide a "brake" to control/pre-
vent unwanted T cell responses through a negative feed-
back mechanism that includes induction of Foxp3 and
regulatory T cells. As a critical step in this process, the ROS
produced by TCR-activated T cells plays a significant role
in converting the latent TGF-β into the biologically active
form, as neutralization/inhibition of ROS with MnTBAP
almost completely abrogates the active TGF-β in the
supernatants and significantly decreases the Foxp3 expres-
sion in activated CD4+CD25- T cells. TCR stimulation
increases the level of ROS in T cells [30,36]. The data that
the culture supernatants in TCR stimulated CD25- T cells
contain large amounts of ROS have provided further evi-
dence that ROS plays a significant role in activation of
endogenous TGF-β produced by T cells, although other
factors may also participate in this conversion. However,
it remains largely unknown where and how ROS is pro-
duced in a T cell, and when and how ROS is released from
the cell. The mitochondria appears to be one of the largest
sources of ROS within cells [34,36,44]. Resting T cells pro-
duce low levels of ROS. TCR activation likely triggers
increased respiratory activity from the mitochondria to
meet the energy requirement for acquisition of effector
cell functions [36]. It is of note that the increase in ROS
production in T cells is concurrent with increased mito-
chondrial membrane hyperpolarization, which may lead
to ROS re-distribution into the cytosol to initiate cell
death. The late apoptotic and/or dead cells may release
ROS into the cultures to activate latent TGF-β [34,35].
Indeed, the apoptotic T cells in the TCR- and CD28-
treated CD4+CD25- T cell cultures accumulate dramati-
cally after 72 hrs, and these late apoptotic/dead T cells
(Annexin-V+7-AAD+) express much higher levels of intra-
cellular ROS than viable and early apoptotic T cells.
Although it is unclear how MnTBAP antagonizes ROS, it is
conceivable that MnTBAP may reduce intracellular ROS
production and abolish the released ROS [32,34,36].
The unexpected finding that HIV infection results in an
increase in Foxp3 expression in TCR activated CD25- T
cells compared to those without HIV infection uncovers a
link between HIV infection and induction of Foxp3 and T
regulatory cells. The Foxp3 upregulation was again pro-
duced through TGF-β in the T cells, since deletion of TGF-
β with anti-TGF-β antibody abrogates the effect. Intrigu-
ingly, despite the reduction in Foxp3+ T cells achieved by
inhibiting endogenous TGF-β induced by HIV, the replica-
tion of the virus was not significantly affected. However,
exogenous TGF-β always inhibits HIV replication in acti-
vated CD4+CD25- T cells in different experimental regi-
mens (Fig. 10B). These data suggest that the dose and the
time are the determining factors for TGF-β in regulating
HIV. Early and sufficient amounts of active TGF-β (e.g
exogenous active TGF-β) present during the initiation of T
cell activation may be required for this effect, whereas the
TGF-β produced following T cell activation/proliferation
might be too late to affect HIV replication in the same cells
(e.g. anti-TGF-β inclusion). Consistent to this notion, it
has been reported that SIVmac infection in macaques
(MACs) is unable to respond to TGF-β1, whereas the non-
pathogenic SIVagm infection in African green Mon-
keys(AGMs) exhibits more sensitivity to TGF-β signaling
characterized by longer lasting upregulation of Smad4
[45]. However, the T cell derived TGF-β and induced
Foxp3+ T regulatory cells may subsequently inhibit thePage 13 of 16
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notion is supported by the observation that HIV replica-
tion in activated natural CD4+CD25+ human T cells (a
mixture of CD25+Foxp3+ regulatory cells and
CD25+Foxp3-non-regulatory T cells) was significantly
delayed compared to that in the parallel CD25- T cells
(unpublished data). Alternatively, TGF-β inhibition of
HIV replication might not be directly associated with
Foxp3 expression, thereby suggesting that Foxp3+ T cells
are equally susceptible to HIV replication [23]. However,
this possibility remains to be investigated. Nevertheless,
our data shed new light on the pathogenesis of HIV infec-
tion by linking the virus with the induction of Foxp3+ T
cells through TGF-β, thereby opening a new avenue to




The human T regulatory cell isolation kit and PE anti-
human CD25 antibody were obtained from Miltenyi Bio-
tech (Auburn, CA). The PE-conjugated Foxp3 antibody
(clone PCH101) for flow cytometric staining and the rat
serum anti-Foxp3 polyclonal antibody for Western blot-
ting were obtained from eBioscience (San Diego, CA). The
following antibodies were purchased from BD Bioscience
(San Diego, CA): purified mouse anti-human CD3 (clone
UCHT1; NA/LE™), purified mouse anti-human CD28
(clone CD28.2; NA/LE™), FITC anti-human CD25 (clone
M-A251), FITC anti-human CD4 (clone RPA-T4), PE anti-
human CD45RO (clone UCHL1), APC anti-human IL-4
(clone MP4-25D2), APC anti-human IFN-γ (clone B27),
and the corresponding isotype-matched negative controls.
Anti-phosphorylated Smad2 antibody was from Cell Sig-
naling (Danvers, MA); the biotinylated anti-goat and anti-
rabbit antibodies were obtained from Santa Cruz (Santa
Cruz, CA). Recombinant TGF-β1, anti-TGF-β1,2,3 and
mouse IgG1 isotype control were purchased from R&D
systems (Minneapolis, MN). Dihydroethidium was pur-
chased from Molecular Probes. Manganese (III) tetrakis
(5,10,15,20-benzoic acid) porphyrin (MnTBAP) was pro-
cured from Calbiochem (La Jolla, CA). For detecting ROS,
2'7'-dichlorofluorescin-di-acetate (DCFH-DA) was pur-
chased from Molecular probes (CA, USA). 2',7'-dichlo-
rofluorescein (DCF) was obtained from (Sigma, MO).
DCFH-DA was dissolved in ethanol at a concentration of
10 mg/ml. Stock solutions of DCF were also prepared in
ethanol.
Isolation of subsets of human CD4+ T cells
Human peripheral blood mononuclear cells (PBMC)
were obtained by leukopheresis of normal volunteers at
the Department of Transfusion Medicine at the National
Institutes of Health (NIH, Bethesda, MD). The
CD4+CD25- T cells were isolated using the human T regu-
latory isolation kit from Miltenyi Biotec following the
manufacturer's recommendations. The CD4+CD25- T cell
population obtained was used for all the assays. Purity of
the cells obtained using this method was 98–99% as
determined by flow cytometric screening. For further sep-
aration of the CD25- population, CD45RO beads
(Miltenyi) were used to isolate the CD4+CD25-CD45RO+
and CD4+CD25-CD45RO- T cells. In some experiments,
CD4+CD25- CD45RO- or CD45RO+ T cells were isolated
using a Moflo cell sorter (Dako, Colorado).
Cell culture
Purified CD4+CD25- T cells were cultured in serum-free
culture medium X-Vivo 20 (BioWhittaker, Walkersville,
MD) in 24-well flat-bottom plates. Plates were coated
with mouse anti-human CD3 antibody (5 μg/ml in PBS)
for 3 hrs at 37°C and washed twice with sterile PBS. Solu-
ble mouse-anti-human CD28 (1 μg/ml) was added to all
conditions, recombinant TGF-β1 was added (2 ng/ml) as
one experimental condition, the anti-TGF-β1,2,3 anti-
body (20 μg/ml) was added as another, and the isotype-
matched negative control (mIgG1, 20 μg/ml) in some
other instances. Another experimental condition was set
up in which MnTBAP (100 μM) was added to the culture
in addition to anti-CD3 and anti-CD28 stimulation. With
respect to assays involving CFSE, freshly isolated
CD4+CD25- T cells were incubated with 2.5 μM of CFSE in
PBS at 37°C for 10 mins, washed twice with X-Vivo 20
medium (BioWhittaker), and then used in culture.
Real-time PCR for Foxp3 expression
The cell cultures were harvested after 48 hr and 72 hr, and
real time PCR was performed as described previously(18)
using the cDNA as template for Foxp3 expression and
glyceraldehydes-3 phosphate dehydrogenase (GAPDH)
was used as the internal control. The Foxp3-specific prim-
ers used were 5'-CAG-CAC-ATT-CCC-AGA-GTT-CCT-C-3'
and 5'-GCG-TGT-GAA-CCA-GTG-GTA-GAT-C-3', and the
Foxp3 probe was 5'-FAM-TCC-AGA-GAA-GCA-GCG-
GAC-ACT-CAA-TG-TAMRA. Pre-developed Taqman assay
reagent for human GAPDH was used as the internal con-
trol. Normalized values for Foxp3 mRNA expression in
each sample were calculated as the relative quantity of
Foxp3 divided by the relative quantity of GAPDH.
Western blot analysis
Cells were lysed using cell lysis buffer obtained from
Sigma Aldrich, USA. Western blotting was performed as
previously described [12] with antibodies to Foxp3 (rat
polyclonal IgG, 1:1200), smad2/3 (goat polyclonal IgG,
1:1000), P-Smad2 (rabbit polyclonal IgG, 1:700), TGF-
β1(rabbit polyclonal IgG, 1:1000, Promega), α-tubulin
(mouse polyclonal IgG, 1:2000) and actin (goat polyclo-
nal IgG, 1:1000, Santa Cruz), followed by horseradish
peroxidase-conjugated goat anti-rat IgG, goat anti-mousePage 14 of 16
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ufacturer.
Cytokine determination
For cytokine detection, supernatants were collected from
the T cell cultures. Total and active TGF-β1 present in the
supernatant were determined by ELISA (Promega. WI) as
described previously [34]. A standard curve was generated
using the known amounts of the purified recombinant
TGF-β1 that are provided with the kit.
Flow cytometric staining
The cells were re-suspended in PBS containing 1% BSA
and 0.1% sodium azide. For the staining of cell surface
markers, cells were incubated with FITC or PE antibodies
for 30 mins at 4°C. Isotype-matched negative controls
were used for all flow cytometric analysis. For intracellular
IL-2, IL-4, IFN-γ, and Foxp3 staining, the protocol pro-
vided with the Foxp3 antibody kit was followed (eBio-
science, CA).
Detection of ROS in T cells
The reactive oxygen species (ROS) in T cells was detected
as previously described(Chen et al, 2001). The cells were
resuspended in 1 ml of colorless DMEM containing 2.5
μM dihydroethidium (DHE). The cells were incubated at
37°C for 40 min, washed once with the medium, resus-
pended in PBS containing 1% BSA, and then subjected to
flow cytometric analysis.
Detection of ROS in culture supernatant
The amount of reactive oxygen species present in the
supernatants of the T cell cultures was assessed by measur-
ing the oxidation of DCFH-DA in a Wallac Victor 1420
multilabel counter (Perkin Elmer life sciences, C) at wave-
length 485/535 nm. The instrument was calibrated with
known concentrations of 2',7'-dichlorofluorescein. The
cell-free supernatant from the indicated T cell cultures
were collected. An equal volume (200 μl) of culture super-
natant was taken and DCFH-DA was added at a concentra-
tion of 10 μg/ml in a 96 well flat bottom plate (Costar).
The plate was incubated at 37°C overnight and fluores-
cence measured.
HIV infection in human CD4+CD25- T cells
HIV-1NL4-3 virus was prepared by transfection of HEK293
T cells as previously described [37]. The virus titer
(TCID50 = 104.66/ml) was measured using a Rev-depend-
ent GFP-indicator cell line, Rev-CEM (Ref: Wu and Marsh,
Current HIV Research, 2007). 1 × 106 freshly isolated
human CD4+CD25- T cells were infected with 150 μl of
virus for 2 hours at 37°C, then washed with medium three
times to remove free viral particles. Infected cells were
seeded onto an anti-human CD3 antibody (5 μg/ml)-
coated 24-well plate and cultured with soluble anti-
human CD28 antibody (1 μg/ml) for 5 days. A fraction of
infected cells was simultaneously cultured with TGF-β (2
ng/ml) or anti-TGF-β antibody (20 μg/ml) on the plate,
respectively. Supernatant from infected or uninfected con-
trol cells was collected on day 1, 3, and 5. Viral replication
was measured by HIV p24 ELISA as recommended by the
manufacturer (Beckman Coulter, Fullerton). On days 3
and 5 post-infection, Foxp3/CD25 staining and analysis
was performed by flow cytometry as described above.
Statistical analysis
Student's t tests were used for the significance of data com-
parison.
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